Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

94 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2014-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo.

The patients will be randomized in two groups according to symptomatic treatment modalities: Dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. Each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). The patient will be rate the intensity of symptoms in the following times:

* Numeric rating scale (1 to 10): Admission
* Numeric rating scale (1 to 10): After the study drug (No ambulation)\*
* Numeric rating scale (1 to 10): After the study drug (Ambulation)\*

* Ambulation refers to head movements or walking in the room, if applicable.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo

NCT02253524

Nausea Vomiting Vertigo

COMPLETED PHASE4

Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin

NCT02112578

Vertigo, Peripheral

COMPLETED PHASE3

Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral Vertigo

NCT06293989

Vertigo, Peripheral

NOT_YET_RECRUITING PHASE3

Promethazine vs. Lorazepam for Treatment of Vertigo

NCT01827293

Peripheral Vertigo.

COMPLETED PHASE3

AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery

NCT03908567

Vestibular Vertigo

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Vertigo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Piracetam

2 g intravenous piracetam

Group Type ACTIVE_COMPARATOR

2 g piracetam intravenous

Intervention Type DRUG

Dimenhydrinate

Dimenhydrinate 100 mg intravenous

Group Type ACTIVE_COMPARATOR

Administration of 100 mg dimenhydrinate intravenous

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Administration of 100 mg dimenhydrinate intravenous

Intervention Type DRUG

2 g piracetam intravenous

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presenting to emergency department with vertigo symptoms
* Adult patients (over 18)
* Agree to participate to study (understanding the study protocol and signing the informed consent form)

Exclusion Criteria

* Patients under 18 years
* Patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging
* Patient diagnosed with transient ischemic attack
* Pregnants
* Patients taking any analgesics or antihistaminic drugs last 24 hours
* Documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines
* Patients who do not agree to participate to the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No